Clinical trial NCT00818194: Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers
Official title: A Comparison of Effects of Short-term Low Dose Exposure of Advagraf® and Neoral® Microemulsion Cyclosporine A on Renal Perfusion and Function in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Tacrolimus
cyclosporine A
renal plasma flow
glomerular filtration rate
human
pharmacodynamics
pharmacokinetics
Pharmacodynamics of tacrolimus
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Astellas Pharma Canada, Inc.
First posted: 2009-01-07
Enrollment: 18
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to compare the effects of steady state tacrolimus vs. cyclosporine on renal pharmacodynamics in healthy volunteers.

Detailed description: This study seeks to evaluate the renal physiological responses of short-term maintenance level doses of CNIs in healthy volunteers to determine if daily perturbations in renal physiology exist, and if confirmed, whether they differ between CNIs and thus may contribute by different mechanisms to the progression of CAN.

Eligibility criteria: Inclusion Criteria:

* caucasian
* healthy with no history or current clinical findings of infection or disease of the following nature: cerebrovascular, neurologic, cardiovascular, endocrine, pulmonary, immunologic, metabolic, hematologic, diabetes mellitus, glucose intolerance, gout
* non-smoker and willing to abstain from alcohol consumption during the study
* agrees to use appropriate contraception during the study period until 3 months after the final study exam.

Exclusion Criteria:

* history of significant alcohol abuse or drug abuse within 1 year prior to the screening visit
* regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week)
* use of soft drugs (marijuana) within 3 months prior to the screening visit or hard drugs (cocaine, PCP, crack) within 1 year prior to the screening visit Hepatitis B or C, HIV, history of cancer (excluding excised squamous or basal cell carcinoma)
* positive tuberculin skin test or prior TB infection
* known history of serious head injuries, seizures or any eating disorder
* received an investigational drug within 30 days prior to the first study drug administration
* known hypersensitivity/allergy to tacrolimus, cyclosporine, iothalamate iodine, para-aminohippuric acid, antibiotics or antifungals
* Body mass index (BMI) \<19 or \>27
* clinically significant history of psychiatric disease or a significant disability that prevents understanding or adherence to protocol
* renal dysfunction, serum creatinine or urine microalbumin above the normal age and gender-adjusted reference range of the local lab
* clinically significant abnormal liver function test indicative of impaired hepatic function
* received medications/herbal preparations that may affect the metabolism of tacrolimus or cyclosporine A within 1 month of the first study drug administration
* received any other prescription medication within 14 days prior to the first study drug administration or any over-the-counter product within 7 days prior to the first study drug administration, except for topical products without systemic absorption
* current GI condition known to affect GI motility and/or absorption
* donation of plasma (500 mL) within 7 days prior to the first study drug administration or donation/ loss of whole blood as follows: 50 mL to 499 mL within 30 days or more than 499 mL within 56 days prior to the first study drug administration
* clinically significant surgery within 4 weeks prior to the first study drug administration
* administration of steroids by injection within 12 weeks prior to the first study drug administration
* administration of any live vaccine within 7 days prior to the first study drug administration
* travel in areas where TB is endemic within 8 weeks prior to the TB skin test performed at the screening visit
* hemoglobin \<140 g/L

Primary outcomes:
measure: Comparison of Effective Renal Plasma Flow response
timeFrame: Baseline and Day 10 of each dosing interval
Secondary outcomes:
measure: Comparison of Glomerular Filtration Rate response
timeFrame: Baseline and Day 10 of each dosing interval
measure: Comparison of blood pressure response
timeFrame: Baseline and Day 10 of each dosing interval
Other outcomes:
Locations:
city: Montreal
country: Canada
state: Quebec
Study officials:
affiliation: Astellas Pharma Canada, Inc.
name: Use Central Contact
role: STUDY_DIRECTOR
References: